Medical management of Cushing's disease: What is the future?

Pituitary

Volumn 15, Issue 3, 2012, Pages 330-341

  Fleseriu, Maria ^a   Petersenn, Stephan ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b ENDOC Center for Endocrine Tumors   (Germany)

Author keywords

Cushing's disease; Cushing's syndrome; Mifepristone; Pasireotide; Pituitary adenoma; Somatostatin analog

Indexed keywords

AMINOGLUTETHIMIDE; ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DEXAMETHASONE; DOPAMINE RECEPTOR STIMULATING AGENT; ENZYME INHIBITOR; ETOMIDATE; FLUCONAZOLE; KETOCONAZOLE; LCI 699; METYRAPONE; MIFEPRISTONE; MITOTANE; OCTREOTIDE; PASIREOTIDE; PIOGLITAZONE; ROSIGLITAZONE; SOMATOSTATIN DERIVATIVE; SPIRONOLACTONE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACNE; ACTH SECRETING ADENOMA; ADD ON THERAPY; ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL INSUFFICIENCY; ALKALOSIS; ASTHENIA; AWARENESS; CANCER RADIOTHERAPY; CANCER SURGERY; CHOLELITHIASIS; CLINICAL RESEARCH; CUSHING DISEASE; CUSHING SYNDROME; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MECHANISM; DRUG WITHDRAWAL; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOPHYSIS TUMOR; HYPOTENSION; LETHARGY; LONG TERM CARE; LOW DRUG DOSE; MENTAL CONCENTRATION; MICROADENOMA; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; REOPERATION; REVIEW; SIDE EFFECT; SKIN BRUISING; SOMNOLENCE; TRANSSPHENOIDAL SURGERY; TUMOR RECURRENCE; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

AMINOGLUTETHIMIDE; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; ETOMIDATE; HUMANS; LIGANDS; MIFEPRISTONE; PITUITARY ACTH HYPERSECRETION; PITUITARY GLAND; PPAR GAMMA; RECEPTORS, GLUCOCORTICOID; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 84867399092     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-012-0397-5     Document Type: Review

References (100)

1. Biller BMK et al (2008) Treatment of adrenocorticotropindependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 93(7):2454-2462
2. Tritos NA, Biller BMK, Swearingen B (2011) Management of Cushing disease. Nature Rev Endocrinol 7(5):279-289
3. Patil CG et al (2008) Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 93(2):358-362
4. Clayton RN et al (2011) Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and metaanalysis of literature. J Clin Endocrinol Metab 96(3):632-642
5. Fleseriu M, LoriauxDL, LudlamWH(2007) Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful. Curr Opin Endocrinol Diabetes Obes 14(4):323-328
6. Friedman RB et al (1989) Repeat transsphenoidal surgery for Cushing's disease. J Neurosurgery 71(4):520-527
7. Nieman LK (2007) Medical therapy of Cushing's disease. Pituitary 5(2):77-82
8. Hawn MT et al (2002) Quality of life after laparoscopic bilateral adrenalectomy for Cushing's disease. Surgery 132(6):1064-1069
9. Assie G et al (2007) Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's Syndrome. J Clin Endocrinol Metab 92(1):172-179
10. Petersenn S (2011) Medical management of Cushing's disease. In: Swearingen B, Biller BMK (eds) Endocrine updates vol. 31: Cushing's disease. Springer, New York, pp 167-182
11. Feelders RA et al (2010) Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 362(19): 1846-1848
12. Kamenicky P et al (2011) Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 96(9):2796-2804
13. Deutschbein T et al (2011) Measurement of urinary free cortisol by current immunoassays: need for sex-dependent reference ranges to define hypercortisolism. Horm Metab Res 43(10): 714-719
14. Deutschbein T et al (2012) Salivary cortisol as a diagnostic tool for Cushing's syndrome and adrenal insufficiency: improved screening by an automatic immunoassay. Eur J Endocrinol 166(4):613-618
15. Batista DL et al (2006) The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91(11):4482-4488
16. Greenman Y, Melmed S (1994) Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79(3):724-729
17. Greenman Y, Melmed S (1994) Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 178(2):398-403
18. Hofland LJ et al (2005) The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152(4):645-654
19. Miller GM et al (1995) Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80(4):1386-1392
20. Nielsen S et al (1998) Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas. J Clin Endocrinol Metab 83(8):2997-3000
21. Panetta R, Patel YC (1995) Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 56(5):333-342
22. Strowski MZ et al (2002) Somatostatin receptor subtypes 2 and inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinol 75(6):339-346
23. Stalla GK et al (1994) Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur J Endocrinol 130(2): 125-131
24. Petersenn S et al (1999) Genomic structure and transcriptional regulation of the human somatostatin receptor type 2. Mol Cell Endocrinol 157(1-2):75-85
25. Ambrosi B et al (1990) Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion. J Endocrinol Invest 13(3):257-261
26. Lamberts SW et al (1989) Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinol 50(1):44-50
27. Invitti C et al (1990) Treatment of Cushing's syndrome with the long-acting somatostatin analogue SMS 201-995 (sandostatin). Clin Endocrinol (Oxf) 32(3):275-281
28. Woodhouse NJ et al (1993) Acute and long-term effects of octreotide in patients with ACTH-dependent Cushing's syndrome. Am J Med 95(3):305-308
29. Bruns C et al (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146(5):707-716
30. Schmid HA, Schoeffter P (2004) Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinol 80(Suppl 1):47-50
31. van der Hoek J et al (2005) Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 289(2):E278-E287
32. Silva AP et al (2005) Regulation of ghrelin secretion by somatostatin analogs in rats. Eur J Endocrinol 152(6):887-894
33. Ben-Shlomo A et al (2009) Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab 94(11): 4342-4350
34. Boscaro M et al (2009) Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94(1):115-122
35. Colao A et al (2012) A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 366(10):914-924
36. Signifor (2012) Summary of product characteristics. Novartis, Basel
37. Cukier K et al (2009) Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing's disease. Clin Endocrinol (Oxf) 71(2):305-307
38. Bode H et al (2010) SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes 118(10):760-763
39. Stefaneanu L et al (2001) Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine 14(3):329-336
40. Adams EF et al (1981) Bromocriptine suppresses ACTH secretion from human pituitary tumour cells in culture by a dopaminergic mechanism. Clin Endocrinol (Oxf) 15(5):479-484
41. Yin D et al (1994) Induction of apoptosis in murine ACTHsecreting pituitary adenoma cells by bromocriptine. FEBS Lett 339(1-2):73-75
42. Miller JW, Crapo L (1993) The medical treatment of Cushing's syndrome. Endocr Rev 14(4):443-458
43. Hale AC et al (1988) A bromocriptine-responsive corticotroph adenoma secreting alpha-MSH in a patient with Cushing's disease. Clin Endocrinol (Oxf) 28(2):215-223
44. Koppeschaar HP et al (1986) Response to neurotransmitter modulating drugs in patients with Cushing's disease. Clin Endocrinol (Oxf) 25(6):661-667
45. Pivonello R et al (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89(5):2452-2462
46. Pivonello R et al (2009) The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94(1):223-230
47. Godbout A et al (2010) Cabergoline monotherapy in the longterm treatment of Cushing's disease. Eur J Endocrinol 163(5): 709-716
48. Schade R et al (2007) Dopamine agonists and the risk of cardiac- valve regurgitation. N Engl J Med 356(1):29-38
49. Zanettini R et al (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356(1):39-46
50. Mannelli M et al (2010) Role of the PPAR-gamma system in normal and tumoral pituitary corticotropic cells and adrenal cells. Neuroendocrinol 92(Suppl 1):23-27
51. Heaney AP et al (2002) Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8(11):1281-1287
52. Emery MN et al (2006) PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor. Clin Endocrinol (Oxf) 65(3):389-395
53. Heaney AP (2004) PPAR-gamma in Cushing's disease. Pituitary 7(4):265-269
54. Ambrosi B et al (2004) Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 151(2):173-178
55. Pecori Giraldi F et al (2006) Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease. Clin Endocrinol (Oxf) 64(2):219-224
56. Morcos M et al (2007) Long-term treatment of central Cushing's syndrome with rosiglitazone. Exp Clin Endocrinol Diabetes 115(5):292-297
57. Suri D, Weiss RE (2005) Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab 90(3):1340-1346
58. Nissen SE, Wolski K (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Int Med 170(14):1191-1201
59. Schteingart DE (2009) Drugs in the medical treatment of Cushing's syndrome. Expert Opin Emerg Drugs 14(4):661-671
60. Trainer PJ et al (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342(16):1171-1177
61. Gaillard RC et al (1984) RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitaryadrenal system at a specific time of day. Proc Natl Acad Sci 81(12):3879-3882
62. Gaillard RC et al (1985) RU 486 inhibits peripheral effects of glucocorticoids in humans. J Clin Endocrinol Metab 61(6): 1009-1011
63. Bertagna X et al (1986) Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab 63(3):639-643
64. Johanssen S, Allolio B (2007) Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol 157(5):561-569
65. Castinetti F et al (2009) Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 160(6):1003-1010
66. Chu JW et al (2001) Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 86(8):3568-3573
67. Fleseriu M et al (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab [Epub ahead of print]
68. ClinicalTrials.gov: http://www.clinicaltrials.gov.NCT00936741
69. Belanoff JK et al (2010) Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain. Diabetes Obesity Metab 12(6):545-547
70. Thorn GW et al (1956) Inhibition of corticosteroid secretion by amphenone in a patient with adrenocortical carcinoma. N Engl J Med 254(12):547-551
71. Hertz R, Pittman JA, Graff MM (1956) Amphenone: toxicity and effects on adrenal and thyroid function in man. J Clin Endocrinol Metab 16(6):705-723
72. Liu JK et al (2007) Treatment options for Cushing disease after unsuccessful transsphenoidal surgery. Neurosurg Focus 23(3): E8
73. Liddle GW et al (1958) Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 beta-hydroxylation. J Clin Endocrinol Metab 18(8):906-912
74. Gower DB (1974) Modifiers of steroid-hormone metabolism: a review of their chemistry, biochemistry and clinical applications. J Steroid Biochem 5(5):501-523
75. Sonino N, Boscaro M (1999) Medical therapy for Cushing's disease. Endocrinol Metab Clin North Am 28(1):211-222
76. Verhelst JA et al (1991) Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 35(2):169-178
77. Jeffcoate WJ et al (1977) Metyrapone in long-term management of Cushing's disease. Br Med J 2(6081):215-217
78. Pont A et al (1982) Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med 97(3):370-372
79. Pont A et al (1982) Ketoconazole blocks testosterone synthesis. Arch Intern Med 142(12):2137-2140
80. Feldman D (1986) Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev 7(4):409-420
81. Sonino N (1987) The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 317(13):812-818
82. Castinetti F et al (2008) Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol 158(1):91-99
83. Sonino N et al (1991) Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 35(4):347-352
84. Miettinen TA (1988) Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res 29(1):43-51
85. Glass AR, Eil C (1986) Ketoconazole-induced reduction in serum 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab 63(3):766-769
86. Lake-Bakaar G, Scheuer PJ, Sherlock S (1987) Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J (Clin Res Ed) 294(6569):419-422
87. Lewis JH et al (1984) Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 86(3):503-513
88. Riedl M et al (2006) Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol 154(4):519-524
89. Kaminsky N, Luse S, Hartroft P (1962) Ultrastructure of adrenal cortex of the dog during treatment with DDD. J Natl Cancer Inst 29:127-159
90. Luton JP et al (1979) Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases. N Engl J Med 300(9):459-464
91. Schteingart DE et al (1980) Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Intern Med 92(5):613-619
92. Hague RV, May W, Cullen DR (1989) Hepatic microsomal enzyme induction and adrenal crisis due to o,p'DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol (Oxf) 31(1):51-57
93. Robinson BG et al (1987) The effect of o,p0-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol (Oxf) 27(4):437-444
94. Schulte HM et al (1990) Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 70(5):1426-1430
95. Greening JE et al (2005) Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease. Horm Res 64(3):140-143
96. Heyn J et al (2011) Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate. Pituitary 15(2):117-125
97. Calhoun DA et al (2011) Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase trial. Circulation 124(18):1945-1955
98. Amar L et al (2010) Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 56:831-838
99. Bertagna X et al (2012) Patients with Cushing's disease achieve normal urinary cortisol with LCI699, a potent 11b-hydroxylase inhibitor: preliminary results from a multicenter, proof-of-concept study. Endocrine Abstracts 29 OC1.2. Presented at ICE/ ECE 2012, May 5-9, 2012, Florence, Italy
100. Vilar L et al (2010) Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary 13(2):123-129